- Home
- NEWP vs SLS Comparison
NEWP vs SLS Comparison
Compare NEWP & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEWP | SLS |
|---|---|---|
| Founded | 1972 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 924.5M |
| IPO Year | 2006 | 2007 |
Fundamental Metrics
Financial Performance| Metric | NEWP | SLS |
|---|---|---|
| Price | $5.27 | $7.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $10.00 |
| AVG Volume (30 Days) | 931.5K | ★ 5.7M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $110.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.11 | $1.39 |
| 52 Week High | $6.31 | $7.80 |
Technical Indicators
Market Signals| Indicator | NEWP | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 47.74 | 71.73 |
| Support Level | $4.96 | $1.46 |
| Resistance Level | $5.79 | N/A |
| Average True Range (ATR) | 0.41 | 0.42 |
| MACD | -0.06 | 0.25 |
| Stochastic Oscillator | 22.68 | 76.95 |
Price Performance
Historical ComparisonAbout NEWP New Pacific Metals Corp.
New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.